Everything drug pricing and policy, every day
Plus a look at all the MFN action, from the industry reactions to Democratic positioning to the administration’s sales efforts
The industry's reaction to the call for permanent price controls: 'We’ve seen this movie before'
There are references today to Tom Brady, Mark Cuban, and PBM concentration. Something for everyone!
And PCMA has picked up the pace of its communications, so Cost Curve is going to have to pick up the pace of its fact-checking
Plus obesity news on adherence, vials, and reimbursement in Medicare
And a survey of community oncologists finds near unanimity on the negative impacts of step therapy
And the Trump administration says that it has successfully pushed prices up in Europe, though the evidence of pricing action overseas remains scant
And there are still TrumpRx stories to be told, including an effort by Pfizer to use the platform in a low-key biosimilar price war
And Hims announced a compounded version of Wegovy’s active ingredient, causing reactions from Novo and the FDA
